Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Tax Provisions (2017 - 2025)

Historic Tax Provisions for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to $873000.0.

  • Ultragenyx Pharmaceutical's Tax Provisions rose 18811.88% to $873000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 31490.89%. This contributed to the annual value of $3.0 million for FY2024, which is 26268.49% up from last year.
  • Ultragenyx Pharmaceutical's Tax Provisions amounted to $873000.0 in Q3 2025, which was up 18811.88% from $947000.0 recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Tax Provisions high stood at $6.3 million for Q3 2022, and its period low was -$3.7 million during Q4 2023.
  • Moreover, its 5-year median value for Tax Provisions was $495000.0 (2023), whereas its average is $666000.0.
  • Its Tax Provisions has fluctuated over the past 5 years, first surged by 335439.56% in 2022, then crashed by 205873.02% in 2023.
  • Ultragenyx Pharmaceutical's Tax Provisions (Quarter) stood at $20000.0 in 2021, then soared by 845.0% to $189000.0 in 2022, then plummeted by 2058.73% to -$3.7 million in 2023, then skyrocketed by 136.55% to $1.4 million in 2024, then tumbled by 35.48% to $873000.0 in 2025.
  • Its last three reported values are $873000.0 in Q3 2025, $947000.0 for Q2 2025, and $1.3 million during Q1 2025.